Tazemetostat

Drug Profile

Tazemetostat

Alternative Names: E-7438; EPZ-6438

Latest Information Update: 28 Jun 2017

Price : $50

At a glance

  • Originator Epizyme
  • Developer Eisai Co Ltd; Epizyme; Genentech
  • Class Amines; Antineoplastics; Biphenyl compounds; Dihydropyridines; Morpholines; Small molecules
  • Mechanism of Action EZH2 enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rhabdoid tumour; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Follicular lymphoma; Mesothelioma; Non-Hodgkin's lymphoma; Rhabdoid tumour; Solid tumours; Synovial sarcoma
  • Phase I B cell lymphoma; Mantle-cell lymphoma

Most Recent Events

  • 28 Jun 2017 Epizyme initiates a phase I drug-drug interaction trial in Diffuse large B-cell lymphoma in USA (PO) (NCT03028103)
  • 27 Jun 2017 Interim efficacy and adverse event data from a phase II trial in Haematological malignancies released by Epizyme
  • 21 Jun 2017 Tazemetostat receives Orphan Drug status for Soft tissue sarcoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top